| Price | 62.00p on 03-03-2026 at 19:35:07 |
|---|---|
| Change | 0.00p 0% |
| Buy | 63.00p |
| Sell | 61.00p |
| Last Trade: | Buy 6,100.00 at 62.65p |
| Day's Volume: | 1,502,101 |
| Last Close: | 62.00p |
| Open: | 62.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 61.00p - 62.00p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £271.33m |
| VWAP: | 62.66724p |
| Shares in Issue: | 437.63m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 6,100 | 62.65p | Ordinary |
16:29:02 - 03-Mar-26 |
| Sell* | 36,788 | 61.80p | Ordinary |
16:22:58 - 03-Mar-26 |
| Buy* | 16,051 | 62.30p | Ordinary |
16:19:12 - 03-Mar-26 |
| Buy* | 16,051 | 62.30p | Ordinary |
16:18:52 - 03-Mar-26 |
| Sell* | 1,000 | 61.575p | Ordinary |
16:18:08 - 03-Mar-26 |
| Buy* | 10,000 | 62.30p | Ordinary |
16:15:11 - 03-Mar-26 |
| Buy* | 380 | 62.30p | Ordinary |
16:13:41 - 03-Mar-26 |
| Buy* | 374 | 62.30p | Ordinary |
16:11:32 - 03-Mar-26 |
| Buy* | 36,000 | 62.345p | Ordinary |
16:08:28 - 03-Mar-26 |
| Buy* | 784 | 62.30p | Ordinary |
16:02:15 - 03-Mar-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 24th Feb 2026 7:00 am | RNS | PreCISION payload delivery advantage over ADC |
| 18th Feb 2026 7:00 am | RNS-R | Avacta to Participate in Conference March 2026 |
| 9th Feb 2026 7:00 am | RNS | Appointment of CSO |
| 3rd Feb 2026 7:00 am | RNS | Faridoxorubicin Program Clinical Updates |
| 21st Jan 2026 7:00 am | RNS | FDA Clearance of IND Application for AVA6103 |
| 20th Jan 2026 7:01 am | RNS | Year-end trading update |
| 20th Jan 2026 7:00 am | RNS | Appointment of Nominated Adviser & TVR |
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
